These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 26964144)

  • 1. The changing landscape of biosimilars in rheumatology.
    Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
    Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
    Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
    Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on biosimilars in rheumatology.
    Rischin A; Östör AJ
    Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PANLAR consensus statement on biosimilars.
    Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
    Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Era of biosimilars in rheumatology: reshaping the healthcare environment.
    Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY
    RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in rheumatology: current perspectives and lessons learnt.
    Dörner T; Kay J
    Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
    Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
    J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
    Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
    Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
    Schulze-Koops H; Skapenko A
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
    Uhlig T; Goll GL
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update.
    Araújo FC; Sepriano A; Teixeira F; Jesus D; Rocha TM; Martins P; Tenazinha C; Cordeiro A; Mourão AF; Silva C; Vaz C; Duarte C; Ponte C; Dos Santos FP; Canhão H; Santos H; Pimentão JB; da Silva JC; Pereira J; da Silva JAP; Miranda LC; Oliveira M; Saavedra MJ; Gonçalves P; Falcão S; Capela S; Fonseca JE
    Acta Reumatol Port; 2017; 42(3):219-228. PubMed ID: 28894080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in Dermatology: Current Situation (Part II).
    Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
    Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
    El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
    Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biosimilars in rheumatology and other fields of medicine].
    Milchert M; Fliciński J; Brzosko M
    Postepy Hig Med Dosw (Online); 2014 Jul; 68():970-5. PubMed ID: 25055035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in rheumatology: understanding the rigor of their development.
    Goel N; Chance K
    Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.